DNA play­er Touch­light dou­bles fundrais­ing this year with lat­est round of pri­vate back­ers on board

When the news got out about Touch­light’s $60 mil­lion fi­nanc­ing round in March, the most promis­ing part of it all was the sug­ges­tion that the com­pa­ny could triple the pro­duc­tion of its “dog­gy­bone” DNA and sup­ply up to 1 bil­lion Covid-19 shot dos­es per month.

Now, the com­pa­ny will have more than dou­ble that amount of mon­ey to work with.

The UK-based biotech that makes en­zy­mat­ic DNA an­nounced the ex­ten­sion of its fundrais­ing round to a to­tal of $125 mil­lion, the com­pa­ny an­nounced. This comes at a time when de­mand for syn­thet­ic DNA has grown in the last year. Touch­light says the fund­ing will help it be­come the largest syn­thet­ic DNA man­u­fac­tur­er in the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER